What is the level of liabilities of bioXXmed this year?
bioXXmed has a debt balance of 188,880 EUR this year.
bioXXmed Liabilities 2024
bioXXmed Liabilities
188,880 EUR
bioXXmed Dividend yield
Ticker
T5O.DE
ISIN
DE000A0KFRJ1
WKN
A0KFRJ
In 2024, bioXXmed's total liabilities amounted to 188,880 EUR, a -52.78% difference from the 399,980.01 EUR total liabilities in the previous year.
bioXXmed Aktienanalyse
What does bioXXmed do?
CytoTools AG is a German biotechnology company based in Darmstadt. It was founded in 2000 and has been listed on the Frankfurt Stock Exchange since 2006. The company focuses on the development of innovative therapies for diseases that have been difficult or impossible to treat so far. CytoTools relies on the use of active substances developed based on endogenous (body's own) molecules. A particular focus is on the research and development of active substances for the treatment of diseases based on inflammatory processes. CytoTools works closely with international research and development partners in this area. CytoTools' business model is based on the development and marketing of products based on innovative technologies and active substances. As a biotechnology company, it specializes in the development of patent-protected products and pursues a scalable business model. The company is divided into various divisions. In the "Pharmaceuticals" division, CytoTools develops innovative active substances and drugs for the treatment of diseases such as inflammatory diseases, cancer, or diabetes. An example of this is the active substance DermaPro, which can be used to treat chronic wounds. In the "Medical Devices" division, CytoTools develops medical devices for the diagnosis and therapy of diseases. An example of this is the CytoSorb system, which is used for extracorporeal blood detoxification and thus supports the treatment of severe infectious and inflammatory diseases. The third division of CytoTools is "Diagnostics". Here, the company develops innovative diagnostic tools for early detection of diseases. An example of this is the biomarker-based rapid test DermaPro Inflammation Score, which allows for a quick and reliable assessment of the inflammatory state of wounds. CytoTools has a strong network of partners and cooperation partners. The most important partners include institutions such as Kiel University, Flensburg University, or the Institute of Molecular Biotechnology in Jena. In addition, CytoTools works closely with international partners from the pharmaceutical industry. Overall, CytoTools is an innovative and rapidly growing biotechnology company specializing in the development of patent-protected products and technologies for the treatment of severe and previously incurable diseases. With its strong network of research and development partners and a wide range of products, the company is well-positioned to continue growing and develop new therapy concepts in the future. bioXXmed ist eines der beliebtesten Unternehmen auf Eulerpool.com.Liabilities Details
Assessing bioXXmed's Liabilities
bioXXmed's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating bioXXmed's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing bioXXmed's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
bioXXmed's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in bioXXmed’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about bioXXmed Stock
What were the liabilities of bioXXmed compared to the previous year?
The liabilities of bioXXmed have increased by -52.78% dropped compared to the previous year.
What are the consequences of high debt for investors of bioXXmed?
High liabilities can pose a risk for investors of bioXXmed, as they can weaken the company's financial position and impair its ability to meet its obligations.
What consequences do low liabilities have for investors in bioXXmed?
Low liabilities mean that bioXXmed has a strong financial position and is able to meet its obligations without overburdening its finances.
How does an increase in liabilities of bioXXmed affect the company?
An increase in liabilities of bioXXmed can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
How does a reduction in the liabilities of bioXXmed affect the company?
A decrease in the liabilities of bioXXmed can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
What are some factors that influence the liabilities of bioXXmed?
Some factors that can influence the liabilities of bioXXmed include investments, acquisitions, operating costs, and sales development.
Why is the level of liabilities of bioXXmed so important for investors?
The liabilities of bioXXmed are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
What strategic measures can bioXXmed take to modify the liabilities?
To change its liabilities, bioXXmed can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
How much dividend does bioXXmed pay?
Over the past 12 months, bioXXmed paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, bioXXmed is expected to pay a dividend of 0 EUR.
What is the dividend yield of bioXXmed?
The current dividend yield of bioXXmed is .
When does bioXXmed pay dividends?
bioXXmed pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of bioXXmed?
bioXXmed paid dividends every year for the past 0 years.
What is the dividend of bioXXmed?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is bioXXmed located?
bioXXmed is assigned to the 'Health' sector.
Wann musste ich die Aktien von bioXXmed kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of bioXXmed from 5/26/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 5/26/2024.
When did bioXXmed pay the last dividend?
The last dividend was paid out on 5/26/2024.
What was the dividend of bioXXmed in the year 2023?
In the year 2023, bioXXmed distributed 0 EUR as dividends.
In which currency does bioXXmed pay out the dividend?
The dividends of bioXXmed are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von bioXXmed
Our stock analysis for bioXXmed Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of bioXXmed Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
